Developing the VUMC MICRO facility to advance innovative BSL3 research

开发 VUMC MICRO 设施以推进创新 BSL3 研究

• 批准号: 10596928
• 负责人: Eric P Skaar
• 金额: $ 797.5万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10596928
• 关键词: Academic Medical Centers; Air; Basic Science; Biomedical Research; COVID-19; Centers for Disease Control and Prevention (U.S.); Communicable Diseases; Ensure; Equipment; Filtration; Goals; Health; Heart; Human; Immunology; Individual; Infection; Inflammation; Infrastructure; Institutes; Institution; Investments; Laboratories; Leadership; Mechanics; Modernization; Pathogenesis; Plumbing; Prevention Guidelines; Procedures; Public Health; Research; Research Personnel; Resources; Silver; Southeastern United States; System; Tennessee; United States National Institutes of Health; Universities; Vaccine Design; Virulent; Work; biosafety level 3 facility; clinical care; design; exhaust; experience; flexibility; innovation; medical schools; microbial; operation; pathogen; research facility; response; square foot; therapeutic development

PROJECT ABSTRACT In response to the global increase and spread of infectious disease and its impact on human health, Vanderbilt University Medical Center (VUMC) has established a trans-institutional strategic framework for infection and immunology research, including significant investments in research focused on highly virulent pathogens. Vanderbilt investigators are rapidly advancing discovery in the fields of microbial pathogenesis, therapeutic development, and vaccine design including critical research combatting COVID-19. Vanderbilt’s growing leadership in microbial pathogenesis makes research at biosafety level 3 (BSL3) critical to enabling breakthroughs. However, Vanderbilt’s two small BSL3 laboratories serve individual investigators and operate at capacity. Most Vanderbilt researchers therefore have no access to BSL3 facilities. The proposed Microbial Infectious Disease Core ResOurce (MICRO) will be a modern, comprehensive BSL3 shared research facility that significantly expands capacity for BSL3 research at Vanderbilt. Regional partnerships with institutions such as the University of Tennessee and Meharry Medical College will advance BSL3 work across the southeastern United States to maximize the MICRO’s benefit and impact. Key project goals will be accomplished through the renovation of 3,587 net square feet (NSF) of space in the heart of Vanderbilt’s biomedical research zone. The MICRO will be flexibly configured to meet stringent isolation requirements for BSL3 and Select Agent pathogens and can be rapidly modified as research and public health needs evolve. The MICRO will contain three BSL3 suites with a total of seven procedure rooms and will be served by new and/or rerouted mechanical and plumbing systems that completely isolate the BSL3 space. A 1,038 NSF BSL3-dedicated space will be constructed to enclose new mechanical equipment, including dedicated air handling units and an exhaust filtration system. The project will be designed to meet LEED Silver standards as well as National Institutes of Health and Centers for Disease Control and Prevention guidelines. The MICRO will be developed and managed by an experienced project manager and BSL3 facility manager working with the Vanderbilt Institute of Infection, Immunology and Inflammation, Office of Research, and Scientific Advisory Board to ensure effective planning, operation, and shared access to the new facility. Overall, the requested renovations will enable substantial improvements in infrastructure, capacity, and capabilities for BSL3 experimentation. This facility will enhance infection and immunology research that will lead to scientific breakthroughs in these fields at the nexus of basic research, clinical care, and public health.

项目摘要 范德比尔特大学医学中心（VUMC）回应了传染病的全球增长和传播及其对人类健康的影响，建立了用于感染和免疫学研究的跨机构战略框架，包括针对高度毒性病原体的研究的大量投资。范德比尔特研究人员正在迅速发展在微生物发病机理，热发育和疫苗设计领域的发现，包括关键的研究对抗Covid-19。范德比尔特（Vanderbilt）在微生物发病机理中不断增长的领导能力使生物安全3级（BSL3）的研究对实现突破至关重要。但是，范德比尔特（Vanderbilt）的两个小型BSL3实验室为个别调查人员提供服务，并以手工运作。因此，大多数范德比尔特研究人员无法访问BSL3设施。拟议的微生物传染病核心资源（Micro）将是一个现代，全面的BSL3共享研究机构，可大大扩大范德比尔特BSL3研究的能力。与田纳西大学和梅哈里大学医学院等机构的区域合作伙伴关系将推动整个美国东南部的BSL3工作，以最大程度地提高微观的利益和影响。关键项目目标将通过在范德比尔特的生物医学研究区中心的3,587净平方英尺（NSF）改革来实现。该微型将被弹性配置为满足BSL3和SELECT ATENT病原体的严格隔离要求，并且随着研究和公共卫生需求的发展，可以快速修改。该微型将包含三个BSL3套件，总共有七个程序室，并由新的和/或重新路由的机械和管道系统提供，这些系统将完全隔离BSL3空间。将建造一个1,038 NSF BSL3-划定的空间，以封闭新的机械设备，包括专用的空气处理单元和排气过滤系统。该项目将旨在符合LEED银标准以及国立卫生研究院和疾病控制与预防指南中心。该微型将由经验丰富的项目经理和BSL3设施经理开发和管理，与范德比尔特感染研究所，免疫学和炎症，研究办公室和科学咨询委员会合作，以确保有效的计划，运营并共享对新设施的访问。总体而言，所要求的改革将使BSL3实验的基础架构，能力和能力进行实质性改善。该设施将增强感染和免疫学研究，这将导致基础研究，临床护理和公共卫生联系的这些领域的科学突破。